USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/33044
Title: Lung transplantation in the management of cystic fibrosis
Authors: Rotaru, Ludmila
Rotaru, Tudor
Keywords: Cystic fibrosis;lung transplantation;post-transplant survival
Issue Date: 2026
Publisher: CEP Medicina
Citation: ROTARU, Ludmila and Tudor ROTARU. Lung transplantation in the management of cystic fibrosis. In: Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026. Chișinău : CEP Medicina, 2026, p. 53. ISBN 978-9975-82-477-4 (PDF).
Abstract: Introduction. Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the CFTR gene, affecting multiple organs, particularly the lungs, and leading to progressive respiratory failure. Despite therapeutic advances, some patients progress to advanced stages of the disease, for whom lung transplantation represents the only option with a significant impact on survival. Materials and Methods. A narrative synthesis of specialized literature was conducted using GeneCards, PubMed, the National Library of Medicine, and Hinari, focusing on publications from the past 10 years. Results. Analysis of the specialized literature indicates that lung transplantation in patients with advanced CF leads to significant improvements in respiratory function and quality of life. Posttransplant survival is estimated at 80–90% at one year, 78–82.8% at three years, and 69–77% at five years, while long-term survival at 10 years ranges between 50–62%, with a median of approximately 10–10.7 years. Clinical factors, including chronic infections and post-transplant rejection, influence prognosis, whereas lung retransplantation is associated with lower survival compared to primary transplantation, highlighting the importance of rigorous patient selection and optimal timing of intervention. Optimization of perioperative management and personalized immunosuppressive therapy contributes to complication reduction and improved survival. Multidisciplinary coordination of patient management further enhances clinical outcomes and long-term survival. Conclusions. Lung transplantation represents an essential intervention for patients with advanced CF, significantly improving life expectancy. Rigorous perioperative management, personalized immunosuppressive therapy, and multidisciplinary coordination contribute to the reduction of postoperative complications and improved clinical outcomes. Post-transplant risks persist, requiring continuous monitoring and adaptive interventions.
metadata.dc.relation.ispartof: Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026
URI: https://repository.usmf.md/handle/20.500.12710/33044
ISBN: 978-9975-82-477-4
Appears in Collections:Cells and Tissues Transplantation. Actualities and Perspectives: The Materials of the National Scientific Conference with International Participation, the 4 th edition, Chisinau, March 20-21, 2026

Files in This Item:
File Description SizeFormat 
Lung_transplantation_in_the_management_of_cystic_fibrosis.pdf246.41 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback